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Abstract
Evaluation of cancer-therapy efficacy at early time points is necessary for realizing the goal of delivering maximally
effective treatment. Molecular imaging with carefully selected tracers and methodologies can provide the means
for realizing this ability. Many therapies are aimed at inducing apoptosis in malignant tissue; thus, the ability to
quantify apoptosis in vivomay be a fruitful approach. Apoptosis rate changes occur on a fast time scale, potentially
allowing correspondingly rapid decisions regarding therapy value. However, quantification of tissue status based
on apoptosis imaging is complicated by this time scale and by the spatial heterogeneity of the process. Using the
positron emission tomography (PET) tracer 2-(5-fluoro-pentyl)-2-methyl-malonic acid (F-18 ML-10), we present
methods of voxelwise analysis yielding quantitative measures of apoptosis changes, parametric apoptosis change
images, and graphical representation of apoptotic features. A method of deformable registration to account for
anatomic changes between scan time points is also demonstrated. Overall apoptotic rates deduced from imaging
depend on tumor density and the specific rate of apoptosis, a situation resulting in an ambiguity in the source of
observed image-based changes. The ambiguity may be resolved through multimodality imaging. An example of
intracellular sodium magnetic resonance imaging coupled with F-18 ML-10 PET is provided.
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Introduction
Every year, 22,500 new cases of primary brain tumor are diagnosed in
adults in the United States of which 70% are malignant glioblastoma
multiforme (GBM) [1,2]. With treatment, median survival is only 12
to 15 months for GBM and 2 to 5 years for anaplastic astrocytoma.
Motivated by these poor outcomes, new brain cancer therapies are
actively being developed and evaluated. There is a concurrent and
pressing need for methods for accurate and timely assessment of treat-
ment response to both facilitate therapy development and, ultimately,
improve clinical management. However, the development of crucially
needed novel therapies for malignant gliomas as well as improved clini-
cal management critically depends on the availability of quantitative
imaging biomarkers that are predictive of early therapy response.
Because the main purpose of effective cancer therapy is to eliminate
cancer cells, imaging of apoptosis offers a direct way to image therapy
response [3]. This programmed form of cell death is regulated by
several pathways and leads to a removal of the dead cell by macro-
phages. Currently, only two apoptosis radiopharmaceuticals have been
studied in clinical trials for follow-up of tumor treatment: Tc-99m
or I-123–labeled annexin V and F-18–labeled 2-(5-fluoro-pentyl)-2-
methyl-malonic acid (F-18 ML-10).
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F-18 ML-10 is a low–molecular mass compound [molecular
weight (MW) = 206 Da] with an alkyl-malonic acid motif as rec-
ognition site and a small aliphatic “tail” to which F-18 is bound [5].
Although the radiosynthesis comprises two steps, both can be per-
formed rapidly and have a high yield, resulting in a tracer that is
suitable for routine clinical practice. In vitro, tritiated ML-10 (H-3
ML-10) has been shown to selectively cross the plasma membrane of
cells undergoing apoptosis (localizing predominantly in the cytoplasm)
while being excluded from viable cells [6]. These studies suggest that
cell plasma membrane depolarization drives the observed selectivity
of H-3ML-10 for apoptotic cells [6]. Importantly, fluorescence micros-
copy imaging has shown the selective detection of apoptosis to be
true across multiple cell lines and multiple apoptosis-inducing therapies
[6]. Furthermore, preclinical F-18 ML-10 phosphorimaging studies of
mouse stroke tissue sections demonstrated a spatial correlation between
F-18 ML-10 uptake in the infarct region of the mouse brain and ter-
minal deoxynucleotidyl transferase 2′-deoxyuridine 5′-triphosphate
(dUTP) nick end labeling (which detects characteristic apoptotic
DNA fragmentation) histologic analysis of corresponding tissue
sections [5].
In humans, F-18 ML-10 biodistribution shows no specific uptake
in nontarget organs or tissues and a desirable rapid clearance from
blood through the kidneys [4]. It also exhibits high stability in vivo
[7]. Specifically, an analysis of plasma samples from eight human sub-
jects found a 97.5% ± 0.4% unchanged F-18ML-10 fraction 150 min-
utes post-injection [7]. Moreover, Oborski et al. [8] observed a changing
pattern of F-18 ML-10 tracer distribution on PET in a human patient
with GBM at baseline (BL) and at a therapy [radiotherapy (RT) plus
temozolomide chemotherapy] response assessment time point, with
comparatively low background F-18 ML-10 uptake in normal brain.
Similarly, in studies evaluating F-18 ML-10 PET as a novel tool for
the early detection of response of brain metastases to whole-body
radiation therapy at 30 Gy, patients underwent two F-18 ML-10
PET scans, the first before therapy and the second after 9 or 10 frac-
tions of RT (approximately 2 weeks from the start of therapy) [9]. Early
treatment–induced changes in tumor F-18 ML-10 uptake were mea-
sured by voxel-based analysis and then evaluated by correlation analysis
as predictors of the extent of later changes in tumor anatomic dimen-
sions as seen on magnetic resonance imaging (MRI) scans 6 to 8 weeks
after completion of therapy [9]. A highly significant correlation (r = 0.9)
was found between early changes on the F-18 ML-10 scan and later
changes in tumor anatomic dimensions [9].
Imaging therapy-induced apoptosis in tumors presents several chal-
lenges with regard to patient imaging protocols and quantitative response
assessment methodology. For example, apoptosis is inherently a transient
process; therefore, standardization of proper imaging protocols to assess
for peak apoptotic response due to therapy is essential for being able to
distinguish between therapy-induced apoptosis and native tumor cell
turnover. This was first demonstrated by Blankenberg et al. [10] in a
cyclophosphamide-treated murine lymphoma model. Treated tumors
showed increased uptake compared to control 20 hours after therapy
[10]. In terms of response assessment, accumulating evidence suggests
that intratumoral heterogeneity is likely a key to understanding cancer
treatment failure [11]. Tumors are composed of different subpopula-
tions of cells that can harbor very different genotypes and phenotypes,
such as differing degrees of differentiation, growth rates, and response
to various therapeutic interventions [12]. Experimental evidence has
also shown that vascular heterogeneity can be associated with disease
progression, therapeutic response, and malignancy.
Due to the nature of the process, PET imaging of apoptosis
requires specialized patient protocols and analysis methodologies.
In this article, we demonstrate a set of approaches to quantifying
therapeutic response assessment in the context of GBM subjects
receiving F-18 ML-10 PET scans.
Materials and Methods
Subjects
This research was performed under the United States Food and
Drug Administration (US FDA) Investigational New Drug program
with University of Pittsburgh Institutional Review Board approval.
After providing written informed consent, six subjects with newly
diagnosed or first late recurrence of GBM were recruited for this study.
For each patient, treatment consists of RT (200 cGy fractions per day
to a total dose of 60 Gy) and temozolomide (75 mg/m2) on days 1 to
42 and adjuvant chemotherapy with temozolomide (75 mg/m2) on
days 1 to 21 of 12 28-day cycles, beginning on about day 72.
Imaging Protocol
The imaging protocol called for subjects to undergo PET and MRI
scanning sessions at BL, approximately 1 to 2 weeks before therapy
initiation. An identical early therapy assessment (ETA) scan session
was also performed approximately 14 ± 3 days after therapy initiation.
We present results from four subjects at BL and the ETA scan session.
Table 1 contains subject characteristics for all four subjects, including
subject age at time of diagnosis, and overall survival (in months) from
the time of each respective subject’s therapy initiation.
PET acquisition protocol. The F-18 ML-10 tracer was produced
at the University of Pittsburgh PET Facility Radiochemistry Labora-
tory (Pittsburgh, PA) using precursor supplied by Aposense Ltd
(Petach-Tikva, Israel). PET scans were performed on a Siemens HR+
PET system (CTI/Siemens, Knoxville, TN) for a 30-minute interval
commencing 120 minutes after injection of approximately 10 mCi of
the F-18 ML-10 tracer. The 30-minute acquisition interval was sub-
divided into six 5-minute frames. Each data frame was reconstructed
into a 128 × 128 × 63 (axial) matrix with voxel dimensions of 0.21 ×
0.21 × 0.24 cm. Data were processed using the manufacturer’s software
using Fourier rebinning, followed by direct Fourier reconstruction.
Images were smoothed with a 3-mmHann filter. The process included
corrections for attenuation, scatter, random coincidences, and dead
time. The six resulting images (per scan) were examined for motion.
A single 30-minute image was produced by averaging over frames.
MRI acquisition protocol. For each subject, at each time point, a
series of MRI scans were acquired on a Siemens 3T Trio MR scanner.
Data acquired included magnetization-prepared rapid acquisition
Table 1. Subjects.
Subject No. Sex (Male/Female) Age (Yr) GBM Location Overall Survival (Mo)
Subject 1 Male 64 Right frontal 17
Subject 2 Male 72 Left medial temporal 2
Subject 3 Female 58 Right parietal 13
Subject 4 Male 59 Left temporal Alive at 11 mo
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with gradient echo (MPRAGE) MRI and T 1-weighted contrast-
enhanced MRI.
All sodium images were acquired on the 3 Tesla (3T) MRI scanners
(MAGNETOM Trio Tim; Siemens Medical Solutions, Erlangen,
Germany) with a dual-tuned (1H-23Na) volume head coil (Advanced
Imaging Research, Cleveland, OH). Volume-fraction weighted con-
centration of bound sodium was quantified on a subtraction image
related to sodium nuclei with biexponential T 2 relaxation. The sub-
traction image was produced by two single-quantum sodium images
acquired at a very short echo time (TE) of TE1 = 0.44 millisecond
and a short echo time of TE2 = 5 milliseconds, respectively. Each
TE image was acquired in a 10-minute scan using a matrix size of 64 ×
64 × 64 with isotropic three-dimensional resolution of 3.44 mm for
a total field of view of (220 mm)3 [13]. The sodium image at TE1
was also used to quantify total sodium concentration (TSC) calibrated
to the cerebrospinal fluid at 145 mM. The single-quantum sodium
images were reconstructed off-line using custom-developed software.
Since most (>60%) of bound sodium is from the intracellular com-
partment [14], we use the term intracellular sodium concentration
(ISC) to refer to volume-fraction weighted concentration of bound
sodium in this work for investigating therapy-induced changes of
intracellular sodium concentration.
Image Analysis
PET images from both the BL and ETA scans of each subject
were aligned and resliced to match the MPRAGE MRI scan from
the subject’s BL scanning session. A rigid registration was achieved
using the normalized mutual information function available in the
image analysis software PMOD 3.4 (University Hospital Zurich,
Zurich, Switzerland). The result of this process is the coregistration
of each subject’s BL and ETA PET scans. F-18 ML-10 image activity
was normalized by dividing by the mean activity within a large blood-
pool region of interest (ROI) placed in the superior sagittal sinus.
Voxelwise Change Analysis
Identification of analysis voxels. A loose tumor ROI that encom-
passed the entire tumor plus a margin of normal tissue but which
excluded blood vessels, skull, and calvariumwasmanually placed around
the tumor volume. For a voxel to be included in the voxelwise change
analysis, it had to have significant uptake in at least one of the two scan
time points (BL or ETA). Voxels within the ROI were classified as
having significant F-18 ML-10 uptake if the activity within the voxel
was greater than 5 SDs above the mean activity within a background
ROI drawn in an uninvolved region of healthy tissue. The SD was
calculated from all the voxels within the background ROI. The set of
all voxels that were found to have significant activity at either BL or
ETA time points is collectively referred to as the voxel analysis domain.
Fractional change in F-18 ML-10 uptake (R) was computed for
each voxel in the voxel analysis domain as
R =
CETA − CBL
1
2 CETA + CBLð Þ
where CETA and CBL are the normalized ETA and BL F-18 ML-10
concentrations at the voxel. Because a voxel need contain significant
activity at only a single time point to be included in the analysis do-
main, the average activity at BL and ETA is used in the denominator
of R to avoid division by zero or small numbers.
Measures of change. Voxels within the analysis domain were
classified as increasing, decreasing, or unchanging between the ETA
and BL scans on the basis of a 15% threshold. That is, voxels with
R > 1.15 were deemed to have increased, and those with R < 0.85 were
deemed to have decreased. The total numbers of increasing, decreasing,
and unchanging voxels were separately tallied (Table 2). Spatial locali-
zation of increasing, decreasing, and unchanging apoptosis signals was
accomplished by color-coded images. To identify possible additional
features related to apoptosis changes from BL to ETA, a 2-dimensional
(2D) histogram of ETA voxel value versus BL voxel value was produced
for each subject. All voxels with significant uptake at either BL or ETA
or both were included in the histogram.
Deformable Registration of Contrast MRI
MIM Software Inc (Cleveland, OH) has developed patent-pending
technology that enables the operator to produce deformable registra-
tion and also allows the operator to guide deformable registration when
there are large changes in anatomy by identifying the same anatomic
landmark in both image volumes. Using this software, PET images from
two time points can be co-deformed on the basis of CT or MRI defor-
mation, which makes structures the same size and allows direct com-
parison of PET activity on a pixel-by-pixel basis. We employed this
technology to a patient example (subject 4). Using the MIM 5.4 plat-
form, a BLROIwas defined on the subject’s BL F-18ML-10 PETusing
the PET Edge tool, available in MIM 5.4, and transferred to the core-
gistered BL contrast-enhanced MRI. The BL T 1 contrast-enhanced
MRI scan and associated F-18 ML-10 PET scans were co-deformed
to the corresponding ETA T 1 contrast-enhanced MRI. The deforma-
tion transformation was applied to the ROI defined on the BL PET and
overlaid on the ETA contrast-enhanced MRI.
Multimodal, Multitime-Point Assessment of Therapy Response
An ROI was defined on subject 4’s ETA contrast MRI that included
enhancing regions of the tumor. The MRI-defined tumor ROI was
then applied to all F-18 ML-10 and total sodium imaging time points.
Changes in F-18 ML-10 activity between BL and ETA time points
were compared to changes in TSC. A voxelwise scatterplot comparing
the change in these biomarkers was generated. Each point of the voxel-
wise change comparison scatterplot falls into one of four classes: I, cor-
responds to increased sodium concentration and increased F-18ML-10
activity signal; II, corresponds to increased sodium concentration and
decreased F-18 ML-10 activity; III, corresponds to decreased sodium
concentration and decreased F-18ML-10 activity; and IV, corresponds
to decreased sodium concentration and increased F-18 ML-10 activ-
ity. Differences were spatially localized by assigning each voxel within
the tumor ROI a particular color corresponding to scatterplot class.
Table 2. Percentage of Change in Voxel Activity after Therapy.
Subject % Voxels Increased % Voxels Decreased % Voxels With No Change
Subject 1 73.42 15.12 11.46
Subject 2 45.85 29.52 24.63
Subject 3 28.57 21.99 49.44
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Finally, spatial localization of the different biomarker change classes was
accomplished by color-coded images.
Results
Figure 1 shows representative BL MPRAGE, BL contrast-enhanced
MRI, and F-18 ML-10 images for a subject with a recurrent GBM
(subject 1). Increased F-18 ML-10 uptake at ETA compared to BL is
evident. In this case, tracer uptake on the PET image is observed to
correspond to the site of the GBM on the BL contrast-enhanced
MRI. We present this example as a case of a patient who ultimately
had a good therapy response (Table 1). Both images show low non-
specific uptake in normal brain.
Figure 2 shows representative BL and ETA contrast-enhanced
MRI as well as BL and ETA F-18 ML-10 PET scans for two newly
diagnosed patients with GBM. At BL, subject 2 (Figure 2C ) shows a
region of high F-18 ML-10 uptake in the center of the tumor located
in the medial left temporal lobe with comparatively lower uptake
observed on the tumor periphery. The ETA F-18 ML-10 PET scan
(Figure 2D) shows a different pattern of tracer distribution compared
Figure 1. Representative BL MPRAGE MRI (A), contrast-enhanced MRI (B), BL F-18 ML-10 PET (C), and ETA F-18 ML-10 PET (D) images
of subject 1 with right-frontal recurrent GBM. Both the BL and ETA (C and D) F-18 ML-10 PET scans show tracer accumulation that
corresponds to the site of the GBM on the BL contrast MRI. Additionally, both the BL and ETA images show low nonspecific uptake in
normal brain. The ETA scan shows increase in F-18 ML-10 uptake compared to BL.
Figure 2. Representative BL (A and E) and ETA (B and F) contrast-enhanced MRI as well as BL (C and G) and ETA (D and H) F-18 ML-10 PET
scans for subject 2 (A–D) and subject 3 (E–H). As described in the text, assessment of responsebasedonqualitative visual interpretation or even
by a semiquantitative index is ambiguous. Increased uptake on subject 3 ETA scan at the posterior medial border is indicated with an arrow.
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to BL. Specifically, the initial region of high uptake at BL is observed
to decrease, whereas regions of new F-18 ML-10 uptake are ob-
served at ETA compared to BL. At BL, subject 3 (Figure 2G ) shows
focal, intense F-18 ML-10 uptake in the tumor region in the right
posterior temporal lobe. The ETA F-18 ML-10 PET scan (Figure 2H)
shows a different pattern of tracer distribution compared to BL. In this
case, the uptake in the central portion has decreased, but a new region of
F-18 ML-10 uptake is observed at the medial posterior border of the
tumor (Figure 2H , arrow).
Taken together, these images are presented to illustrate challenges in
evaluating therapy response in GBM using F-18 ML-10 PET on the
basis of a qualitative visual interpretation. Whereas subject 1 (Figure 1)
shows a desired global increase in F-18 ML-10 uptake after receiving
therapy (Table 2), both subject 2 and subject 3 (Figure 2) exhibit a
more complex, heterogeneous response. For example, although the
initial region of highest F-18ML-10 uptake is observed to decrease from
BL to ETA for subject 2, a new region of tracer uptake is observed to
appear at ETA on the tumor periphery. On careful inspection of the
BL and ETA contrast-enhanced MRI, it is noted that compared to
BL, the size of the tumor at ETA is larger (Figure 2B) indicating new
tumor and therefore tumor progression. On this basis, given the new
tumor tissue, it is reasonable to suggest that the new uptake in this region
is due primarily to tumor cell turnover associated with progression and
not apoptosis associated with therapy response. This is further supported
by the overall poor survival of subject 2 (Table 1).
Voxelwise Change Analysis
The observation that in one case voxels with BL F-18 ML-10
uptake increase in activity at ETA (Figure 1) indicating a good re-
sponse, whereas in another case new regions of low F-18ML-10 uptake
at ETA spatially correlate with new regions of contrast enhancement
(progression) on ETA MRI, compared to BL (Figure 2, A and B), sug-
gests that a global analysis comparing numbers of voxels that increased
or decreased (Table 2) may not be appropriate for response assessment.
One strategy then is to quantify local, or voxelwise, changes in tracer
uptake between BL and ETA time points. Figure 3A shows a scatterplot
of ETA versus BL voxel activity for subject 2. Each color-coded circle
represents a tumor voxel considered for analysis: voxels that decreased
Figure 3. Voxel changemaps for subject 2. A shows a voxel-by-voxel scatterplot of ETA versusBL activity, color coded to indicate voxels that
decreased by more than 15% (blue), increased by greater than 15% (red), or neither increased nor decreased by 15% (i.e., unchanged;
green). Plate (B) is a representative transaxial slice through the subject’s tumor as seen on the ETA PET scan. The colors correspond
to the change status of voxels between BL and ETA and have the same meaning as in A. The 2D histogram of plate (C) conveys similar
information to that of the scatterplot (A). In plate (C), the density of points in the scatterplot is encoded by color. Plate (D) shows the spatial
location (pink and yellow voxels) of two features (pink and yellow circles) seen in the 2D histogram of plate (C).
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by more than 15% (blue), increased by greater than 15% (red), or
neither increased nor decreased by 15% (i.e., unchanged; green).
Figure 3B shows a representative section of the voxel change map fused
to the subjects’ ETA F-18 ML-10 PET scan. The voxel change map
spatially localizes voxels that increased, decreased, or did not change
between BL and ETA imaging time points.
As a result of the small voxel size of the MPRAGE MRI, the indi-
vidual points on the scatterplot (Figure 3A) are too numerous to visually
distinguish point densities. Therefore, a 2D histogram (Figure 3C) was
generated on the basis of the scatterplot to identify high-density regions
of voxels. Comparison of the 2D histogram with the color-coded
scatterplot shows which of the three classes those voxel densities belong.
On the basis of visual inspection of the 2D histogram, two areas of
high-density voxels were identified indicated by yellow and pink circles.
To spatially identify where these voxels were located (Figure 3D), voxels
within the two high-density regions were mapped to their locations on
subject 2’s ETA F-18 ML-10 PET scan. Voxels in the yellow region
are observed to be located on the tumor periphery, whereas voxels in
the pink region are observed to fall in the tumor interior.
Combined Imaging Biomarkers
In addition to identifying new regions of F-18 ML-10 uptake at
ETA as either therapy-induced apoptosis or spontaneous apoptosis,
additional challenges include distinguishing between a high percent-
age of apoptosis in a small density of tumor cells (e.g., F-18 ML-10
image is acquired after peak apoptotic response to therapy has
occurred) versus a small percentage of apoptosis in a large density
of tumor cells (e.g., native tumor apoptosis). This represents a chal-
lenge for molecular imaging using an apoptosis agent, because low
tracer uptake due to effective therapy and low tracer uptake due to
ineffective therapy may become indistinguishable. One approach to
addressing this challenge is to integrate complementary functional
biomarkers of cell viability from MRI as part of a subject’s response
assessment strategy. Figure 4 shows same-day F-18 ML-10 PET
and sodium MR scans at BL and ETA for subject 4. Because the
sodium MRI and F-18 ML-10 PET images are in alignment, each
voxel at each imaging time point has associated F-18 ML-10 PET
and sodium MRI values. F-18 ML-10 (apoptosis) is observed to
increase at the same location that intracellular sodium (reflecting
Figure 4. Same-day F-18 ML-10 PET and sodiumMR scans at BL and ETA from subject 4. F-18 ML-10 (apoptosis) is observed to increase
at the same location that intracellular sodium (proliferation) decreases (arrow). These results are interpreted as showing decreased
proliferation at the same brain location as increased apoptosis.
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activity of proliferation) decreases. These results are interpreted
as showing decreased proliferation at the same brain location as
increased apoptosis.
Deformable Registration for Accurate Subtraction Analysis
An approach to compensating for structural differences between
images acquired at BL and ETA is to apply deformation matrices
to PET data from contrast-enhanced T 1-weighted MR images,
thereby ensuring that measures obtained at BL and ETA are from
the same voxels. Figure 5 shows a demonstration of the deformable
registration procedure. Deformable registration of contrast MRI
scans was performed using the deformable registration tool available
in the commercially available image analysis software MIM 5.4.
A BL ROI was defined on the subject’s BL F-18 ML-10 PET using
the PET Edge tool and transferred to the coregistered BL contrast-
enhanced MRI. Figure 5A show the coregistered ROI in yellow.
The BL contrast-enhanced MRI was then deformed to the ETA
contrast-enhanced MRI. The deformation transformation was applied
to the ROI defined on the BL PET and is shown overlaid on the
ETA contrast-enhanced MRI in Figure 5B. For comparative pur-
poses, Figure 5C shows the original undeformed ROI (yellow) and
the deformed contour (red) overlaid on the undeformed BL contrast-
enhanced MRI. Figure 5D further highlights differences in ROI defini-
tion methods. Specifically, regions of significant difference between the
undeformed BL contour and the deformed ROI are highlighted in
light blue and overlaid on the ETA contrast-enhanced MRI.
Multimodal, Multitime-Point Assessment of Therapy Response
Figure 6 demonstrates an example of a multimodal (F-18 ML-10
PET and sodium MRI), multitime-point (BL and ETA) assessment
of GBM therapy response. Subject 4’s ETA contrast MRI (Figure 6A)
was used to define an ROI around the enhancing region of tumor.
Changes in F-18 ML-10 activity between BL and ETA time points
were compared to changes in TSC. Figure 6B shows a voxelwise
scatterplot comparing the change in F-18 ML-10 and TSC biomarkers
in the contrast-enhanced defined tumor ROI.
Discussion
Quantification of noninvasive in vivo imaging techniques to measure
apoptosis is an important goal for the early detection of many disease
processes in humans. To better understand the biologic underpinnings
and imaging challenges central to the measurement of apoptosis, it
needs to be recognized that the apoptotic process has unique properties
Figure 5. Contour deformation on subject 4. A BL ROI is defined on the BL F-18 ML-10 PET and transferred to the coregistered BL contrast-
enhanced MRI (A). The BL contrast-enhanced MRI is then deformed to the ETA contrast-enhanced MRI, and deformation transformation is
applied to the ROI defined on the BL PET. The deformed BL ROI is then overlaid on the ETA contrast-enhancedMRI (B). C shows the original
undeformed ROI (yellow) and the deformed contour (red) overlaid on the undeformed BL contrast-enhanced MRI. D highlights regions of
significant difference (blue) between the undeformed BL contour and the deformed ROI, overlaid on the ETA CE MRI.
Figure 6. Example of a multimodal (F-18 ML-10 PET and sodium MRI), multitime-point (BL and ETA) assessment of GBM therapy re-
sponse. Subject 4’s ETA contrast-enhanced MRI (A) was used to define an ROI around the tumor. The ROI was applied to the same-time
coregistered sodium (Na) MR and F-18 ML-10 PET scans at the BL and ETA time points. A scatterplot was used to evaluate multiparameter
change for the contrast-enhancedMRI–guided ROI (B). Differences were represented in a four-quadrant scatterplot by assigning each voxel
within the tumor ROI a particular color corresponding to scatterplot class (class I, blue; class II, green; class III, yellow; and class IV, red).
To spatially localize changes, color-coded change maps were generated for the ROI volume and fused to the ETA contrast-enhanced MRI.
Plate (C) shows a contrast-enhanced MRI section with the color-coded change parameters (color code is same as in B). Plate (D) shows a
zoomed-in version of C.
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that differ from other better understood “monotonic” molecular pro-
cesses (such as reduction of F-18–labeled fluorodeoxyglucose uptake as
a biomarker for reduced cellular metabolism) and imaging techniques
currently employed for the assessment of therapy response in cancer
[3,14]. Most importantly, apoptosis is an ephemeral process with a rela-
tively short duration of existence between the time of initiation and
ultimate cell death. Thus, the imaging challenge posed by this intrinsic
dynamic change in tumor cell population apoptotic states must take this
into account. Essentially, a population of cells undergoing apoptosis at
BL will be nonexistent at follow-up, whereas a new population of cells
will be undergoing new apoptosis as a result of effective therapy, but the
net change in macroscopic signal may be little changed [9].
Therefore, it is evident that novel approaches to image quantifica-
tion will be required to assess for therapy response, as typically mea-
sured by a change in tracer uptake distribution from BL to some time
interval after therapy institution. In addition, timing following therapy
is important, because time of apoptosis induction depends both on the
specifics of the type of tumor cell, and therapy. Moreover, the hetero-
geneous tumor environment will likely play a key role in determining
response to therapy, which introduces the requirement for a voxel-
based analysis approach.
In addition to these challenges, neuro-oncology has additional
difficulties. For example, intactness of the blood-brain barrier is a
known issue with regard to transport of both PET tracers (e.g., F-18
fluorothymidine) and therapy. The analysis presented in this manu-
script is a step on the road toward more refined methods that will
incorporate early-time dynamic data, which may provide a method
to identify regions with sufficient blood-brain barrier penetration. For
example, one approach is to calculate the kinetic rate parameter K 1.
In this article, we have outlined imaging methods and analysis
approaches that may afford investigators the opportunity to use
this important imaging biomarker for the purposes of early therapy
response assessment in cancer, specifically GBM. Procedures in-
cluded commonly employed “standard” methods such as multi-
modality rigid image registration. However, the emphasis of this
work is on less commonly used methods that could help to maxi-
mize the utility of apoptosis imaging. Although the complexity of
apoptosis imaging accentuates the need for advanced image analysis
techniques, traditional molecular imaging may also benefit from
similar approaches.
A main tool used in the evaluation of overall therapy response
between BL and ETA was tallying up changes occurring at an in-
dividual voxel level. Such procedures, compared to using average
tumor quantities, may help to extract the spatially heterogeneous
and temporally rapidly changing signal associated with the apoptosis
process. An example of the use of values so determined is illustrated
by Table 2, which lists whole-tumor indices deduced from a two–
time-point, voxelwise analysis. Voxelwise analysis can also be used
to provide parametric images and graphical representations of status
changes, as illustrated by Figure 3. In this analysis, F-18 ML-10
activity change from BL to ETA for each voxel was normalized by
the average of the BL and ETA activities on a voxel-by-voxel basis.
This comparative approach was chosen to avoid division by small
numbers as a result of very low F-18 ML-10 normal brain count
activity. For example, if a voxelwise fractional change with respect
to BL metric [e.g., (ETA − BL)/BL] is used to quantify change in
activity between time points, subject 2 (Figure 2, C and D) would
demonstrate a very high increase in activity at the periphery compared
to BL, which could be falsely interpreted as apoptosis due to effective
therapy. In the case presented in Figure 2, the tumor increased in size
(Figure 2, A and B), and the patient progressed (Table 1).
The use of a voxelwise analysis approach imposes some methodo-
logical impediments. In particular, image-registration accuracy is likely
to be of consequence. Although intrasubject rigid registration methods
are now relatively robust, the possibility of structural change in the
interval between scans may impose a requirement for more sophisti-
cated methods. A commercially available deformable registration
method to address this was used for part of the data analysis. The
results are illustrated in Figure 5. The application of deformable
registration methods is intended to align the same tissue at two differ-
ent time points. However, in light of the changing morphology asso-
ciated with brain tumors, the utility of deformable registration for this
purpose is limited. This method should be used with caution if there
is a long time between BL and ETA scans or if there is an obvious
significant anatomic change. In the future application of this approach,
we anticipate that the time between the BL and ETA scans will be
short, on the order of a few days. An advantage of apoptosis imag-
ing is that we expect tumor apoptotic response to therapy, but not
anatomic changes, to occur on this time scale [15].
A complication in apoptosis imaging for gauging therapy response
is that image intensity is a function of both tumor density and apop-
tosis rate. For example, an increase in image intensity at any particular
voxel could be due to increasing specific apoptosis rate (which, in a
GBM early response assessment, would generally be considered favor-
able) or due to increasing tumor load (unfavorable) or to some com-
bination. Resolving this confound requires additional information, for
example, a measure of cellular proliferation. There are several possible
approaches toward obtaining the required data. In this work, we made
MR-based voxelwise measurements of changes in ISC. The joint
results of sodium MR and F-18 ML-10 PET imaging are illustrated
in Figure 4.
We note that the advent of dual-modality PET/MR may increase
the clinical feasibility of obtaining joint imaging measures. Specifically,
simultaneous 3T PET/MR is now possible in commercially available
scanners. This can allow for same-time acquisition of other valuable
biomarkers of therapy response, such as sodium. Although, to the date
of drafting this paper, sodium imaging is not available on the inte-
grated PET/MR scanners, it is likely to be available in the near future.
The concentration of sodium is elevated in tumors relative to normal
tissues due to increased intracellular sodium (reflecting membrane
depolarization during mitosis and dysfunction of Na+-K+ pumps on
the membrane) and/or an increased proportion of extracellular space
(reflecting changes in cell morphology). Sodium MRI can exploit these
properties to differentiate cancers fromnormal tissues with higher spatial
resolution and signal to noise ratio than magnetic resonance spectro-
scopy [16] as well as assess changes in proliferative and/or cell volume
fraction that occur in tumors and normal tissues after anticancer treat-
ment. Triple-quantum filtering is usually used to detect the alteration
of ISC, but it is limited in use due to its high specific absorption rate
and long scan time (∼40 minutes at 3T) that is difficult for patients
to tolerate. In the results shown here, we employed an alternative
approach to intracellular sodium by using short-T 2 imaging method
that produced low specific absorption rate and required a much
(75%) shorter scan time than typical triple-quantum filtering imaging.
We propose a multimodal (F-18 ML-10 PET and sodium MRI),
multitime-point (BL and ETA) approach to assessment of GBM
therapy response. Figure 6 illustrates methods for displaying changes
in complementary imaging biomarkers, in this case, sodium MRI
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and ML-10 PET, from such an approach. In one display method
(Figure 6B), differences are represented in a four-quadrant scatterplot
by assigning each voxel within the tumor ROI (defined on the basis
of a vascular parameter, in this case, contrast enhancement) a par-
ticular color corresponding to scatterplot class. In a second method
(Figure 6C ), spatially localized color-coded change maps are dis-
played on the ETA contrast-enhanced MRI. A future aim of our work
is to correlate the two biomarkers with patient outcome. We specu-
late that patients exhibiting a relatively high F-18 ML-10 uptake
and relatively low ISC (an example is of intracellular sodium; data is
shown in Figure 4), both compared to BL, indicates a good response
to therapy.
In conclusion, quantification of F-18 ML-10 brain scans may pro-
vide a novel approach for early response assessment and afford the
patient’s optimum management of their cancer therapy. Imaging
apoptotic response to therapy is likely to require novel methods of
analysis, and the purpose of this article was to lay foundation for that.
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